Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Published:2018-09-01 Issue:9 Volume:4 Page:1199
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Joensuu Heikki¹,Fraser Judith²,Wildiers Hans³,Huovinen Riikka⁴,Auvinen Päivi⁵,Utriainen Meri¹,Nyandoto Paul⁶,Villman Kenneth K.⁷,Halonen Päivi¹,Granstam-Björneklett Helena⁸,Lundgren Lotta⁹,Sailas Liisa¹⁰¹¹,Turpeenniemi-Hujanen Taina¹²,Tanner Minna¹³,Yachnin Jeffrey¹⁴,Ritchie Diana²,Johansson Oskar¹⁵,Huttunen Teppo¹⁶,Neven Patrick³,Canney Peter²,Harvey Vernon J.¹⁷,Kellokumpu-Lehtinen Pirkko–Liisa¹³,Lindman Henrik¹⁸

Affiliation:

1. Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

2. Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

3. University Hospitals Leuven, Leuven, Belgium

4. Department of Oncology, Turku University Central Hospital, Turku, Finland

5. Department of Oncology, Kuopio University Hospital, Kuopio, Finland

6. Päijät-Häme Central Hospital, Lahti, Finland

7. Örebro University Hospital, Örebro, Sweden

8. Västerås Central Hospital, Västerås, Sweden

9. Skåne University Hospital, Lund, Sweden

10. Vaasa Central Hospital, Vaasa, Finland

11. North Carelia Central Hospital, Joensuu, Finland

12. Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland

13. Department of Oncology, Tampere University Hospital, Tampere, Finland

14. Eskilstuna Hospital, Eskilstuna, Sweden

15. Landspitali University Hospital, Reykjavik, Iceland

16. 4Pharma, Turku, Finland

17. Auckland City Hospital, Auckland, New Zealand

18. Uppsala University Hospital, Uppsala, Sweden

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference30 articles.

1. Trastuzumab containing regimens for early breast cancer.;Moja;Cochrane Database Syst Rev,2012

2. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.;Perez;J Clin Oncol,2014

3. Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis.;Long;Oncologist,2016

4. Trastuzumab-related cardiotoxicity among older patients with breast cancer.;Chavez-MacGregor;J Clin Oncol,2013

5. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study.;Goldhar;J Natl Cancer Inst,2015

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective;Current Oncology;2023-12-14

2. Breast Cancer;Geriatric Medicine;2023-12-05

3. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial;Journal of Clinical Oncology;2023-11-10

4. Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper;Clinical Breast Cancer;2023-10

5. Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories;Journal of Personalized Medicine;2023-09-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3